NKX101 - CAR NK cell therapy
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory AML
Conditions
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Trial Timeline
Sep 21, 2020 → Jul 1, 2039
NCT ID
NCT04623944About NKX101 - CAR NK cell therapy
NKX101 - CAR NK cell therapy is a phase 1 stage product being developed by Nkarta for Relapsed/Refractory AML. The current trial status is active. This product is registered under clinical trial identifier NCT04623944. Target conditions include Relapsed/Refractory AML, AML, Adult, MDS.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory AML were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04623944 | Phase 1 | Active |
Competing Products
20 competing products in Relapsed/Refractory AML